Introduction
Systemic fungal infection related to fluconazole-resistant yeasts are emerging in immunocompromised patients on fluconazole prophylaxis. [1] These pathogenic yeasts include Trichosporon cutaneum, Blastoschizomyces capitatus, Geotrichum, Stephanoascus ciferrii, Kodamaea ohmeri, etc. The risk factors for the infection with these yeasts include haematologic malignancies, corticosteroid use, hemochromatosis, granulocyte function deficiencies, end-stage renal disease, etc. Their clinical presentation, course and dissemination usually are indistinguishable from candidemia. [1, 2] These infections (except Kodamaea spp.) are associated with extraordinarily high mortality rate and resistance or decreased susceptibility to amphotericin B, fluconazole, itraconazole and echinocandins. Furthermore, infection by these emergent pathogens require expedient diagnosis, antifungal therapy with triazoles (posaconazole, voriconazole and ravuconazole) and amphotericin B. [3] October-December 2015 Antifungal susceptibilities of the isolates to amphotericin B, fluconazole, itraconazole, voriconazole were determined using Clinical and Laboratory Standards Institute (CLSI) M-27 S3 microdilution method. The MICs were defined as the lowest drug concentrations that resulted in complete inhibition of growth. [12] Since, these are uncommon pathogenic yeasts; reconfirmation was performed at National Culture Collection for Pathogenic Fungi, Department of Medical Microbiology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, by sequencing. The DNA of the isolates was amplified by polymerase chain reaction (Genei, Bengaluru, India) and sequenced using the BigDye Terminator Cycle (Applied Biosystems, Foster City, CA, USA). Sequences analysis of the 5.8 S rDNA was done on the genetic analyser 3130 (Applied Biosystems) by using universal primer ITSI and ITS4. [13] Result Clinico-epidemiological and antifungal susceptibility profile of the patients are shown in Table 1 . Only two patients (case 6, 7) were treated successfully after therapy with voriconazole and amphotericin B. The isolates included: Trichosporon spp. (2), S. ciferrii (1), K. ohmeri (1), P. kutrawersi (2), C. rugosa (1) and C. lusitaniae (1) .
Seven out of eight yeasts were also sequenced. Trichosporon spp. in case 1 spp. was sequenced using ITSI and ITS2 primer. It proved to be T. japonicum (accession no.: AF444473), showing 99% homology with CB 58641 strain. The case-3 yeast was sequenced as K. ohmeri (accession no. FJ 21865) showing 99% maximum identification. The case-4 yeast proved to be S. ciferrii (accession no: AY493445) showing 98% homology. C. rugosa in case 5 was sequenced using ITSI and ITS2 primer. It proved to be C. rugosa. The case-5 yeast was sequenced as C. lusitaniae. The case-7 and case-8 yeasts proved to be Pichia kutrawersii.
Discussion
The concerns regarding systemic infections caused by unusual fungi have grown as the population of immunocompromised patients has increased. Five patients (case 1, 2, 4, 5, 8) expired before the result of culture or sensitivity reached clinicians. Furthermore, in all the isolates the exact identification was done after at least 7 days of isolation, initial isolate as non-albicans Candida spp. followed by carbon and nitrogen assimilation test giving the tentative diagnosis at the species level. Subsequently, the isolates were sequenced and reconfirmed.
In this case series the T. japonicum and T. ashaii isolates were cultured from ICU patients on broad spectrum antimicrobials, CVC, ventilator and had prolonged ICU stay. The underlying conditions in these patients were ALL (1) and AML (1) . Other risk factors documented are AIDS, extensive burns, intravascular catheters (biofilm formation), corticosteroids and cardiac surgery. [4] Both these isolates were resistant to azoles but only T. asahii was resistant to amphotericin B. The incidence of Trichosporon infection in patients with leukaemia reported in the literature is 0.4% in a previous multicentre study. [14] However, in India the data pertaining to the isolation of these unusual invasive yeasts is scarce. [8, 9, 15] Trichosporon spp. are among the most common of the non-candida, non-cryptococcus yeasts isolated from clinical specimens throughout the world. [14] The most common cause of trichosporonnosis world-wide is T. asahii followed by T. cutaneum, T. oviodes. [16] The pathogenesis and progression of trichosporonosis in ICU is similar to candidiasis. [4, 16] Unlike candidemia, the recommended guidelines of treatment for trichosporonosis are yet to be established because of the rarity of this infection. Furthermore, Trichosporon spp. are relatively resistant to antifungals including amphotericin B, fluconazole, itraconazole, flucytosine, caspofungin but are susceptible to newer triazoles [4, 16] as were seen this case series. The overall treatment includes voriconazole, catheter removal and in the neutropenic patient administration of granulocyte-macrophage colony-stimulating factor.
Pichia (Kodamaea) ohmerii, a teleomorphic form of Candida guilliermondii var. membranifaciens is environmental yeast and was until now considered a contaminant but now it has emerged as a significant pathogen. [16] First documented a case of K. ohmeri fungemia was reported in 1998. [17] K. ohmeri is now implicated in fungemia, endocarditis, cellulitis, wound infection, catheter infection, peritonitis, phlebitis, urinary tract infection in immunocompromised patients. It has been isolated from tracheal aspirate, wound, CVC. The pre-existing condition documented for infection are implants (CVC, dialysis catheter, pacemaker), cancer with chemotherapy with or without neutropenia, immunosuppression, prematurity, intravenous drug abuse, diabetes, prolonged hospitalisation and abdominal surgery. [18] [19] [20] [21] [22] In this case series, ALL on chemotherapy with neutropenia were the risk factor. The isolate was susceptible to amphotericin B, voriconazole and showed decreased susceptibility to fluconazole and itraconazole. These findings are in concurrence with results of the previous study. [18] In contrast to Pichia anomola, only one nosocomial outbreak due to P. ohmeri has been described. [23] The isolate from the patient was identified as K. ohmeri, showing 100% homology with K. ohmeri using ITS1 and ITS2 sequences. This was also observed by a prior study. [21] In this case series, S. ciferrii were isolated from blood of an AML patient. S. ciferrii has previously been isolated from blood, wound swab, aural discharge and nail sample. Principal sites of infection reported are in ear infections, patients with AML, immunodeficiency patients, superficial and deep mycosis. [5, 6, 18, 21] Although this species has a strong tendency to become resistant especially in patients on fluconazole prophylaxis. However, in our case series the isolate was resistant to amphotericin B but susceptible to fluconazole and itraconazole despite being on fluconazole prophylaxis. Therefore, in vitro susceptibility testing is mandatory for the selection of an appropriate antimycotic drug. Although commercial kits are designed to identify common yeasts, but they fail to characterise these less frequent ones. Molecular methods using ITS1 and ITS2 are an effective tool, [17] as the strain in this case series was characterised using ITS1 and ITS2 region.
The teleomorphic genus Pichia is ascomycetous yeast found in plants, fruits, soil and organic material. Human infections are usually sporadic, but outbreaks have been reported from India and elsewhere. The two species associated with human infection are P. anomola and P. (Kodomaea) ohmeri. [24] Isolation of P. kutrawersii (which is telemorph of C. krusei) in two cases of fungemia in AIDS cases on fluconazole prophylaxis in this study calls for a reappraisal of the risk factors involved in this infection. Amphotericin B with or without flucytosine remains the drug of choice. Fluconazole, itraconazole have moderate activity as were seen in this case-series.
Until recently, C. rugosa was isolated as a single case report or occasional outbreaks as the risk factors such as CVCs, surgical interventions and use of broad-spectrum antibiotics. [24] However, the emergence of this species as a major (20%) cause of candidemia in a major trauma centre in Delhi is a matter of grave concern. [25] This was probably attributed to its isolation from milk of mastitic cows, thereby leading to intestinal colonisation as speculated by an editorial from United Kingdom. [26] In this study, the C. rugosa isolate was resistant to fluconazole and itraconazole, but susceptible to voriconazole, amphotericin B. Similar results were obtained in the prior Indian study. [25] In this case series, C. lusitaniae were isolated from a case of Hodgkins lymphoma. It was resistant to amphotericin B, fluconazole and itraconazole. Most infections with C. lusitaniae have been in patients with hematologic malignancies with neutropenia and stem cell transplant. [27] The polyene resistance is attributed to defect in ergosterol biosynthesis. [4] It has been documented that few C. lusitaniae, even though originally susceptible to amphotericin B, might be less amenable to amphoterecin B therapy. [27] ITS region is an essential and effective tool for differentiating the rare species most frequently misdiagnosed, bearing in mind that reliable sequence databases should be used. Given the inability of phenotypic methods to distinguish some of these rare species, it is possible that molecular methods may ultimately become the primary means of identification of clinically important rare yeasts. As their mistaken identify could imply inappropriate treatment and clinical management.
Conclusions
In laboratories where molecular tests like sequencing are not available, antifungal susceptibility should be provided to clinician and the rare yeast isolates characterised by phenotypic methods be submitted to references laboratories as a cost effective alternative measures, as was followed in this case-series. As these rare species are inherently resistant to antifungal agents and they may lead to the development of nosocomial outbreaks, therefore, accurate identification followed by antifungal susceptibility testing is crucial for proper treatment and management.
